Clinical efficacy of drug-coated balloons in the treatment of infrapopliteal artery disease in hemodialysis patients
10.3760/cma.j.cn113855-20240528-00388
- VernacularTitle:药物涂层球囊治疗透析患者膝下动脉病变的临床分析
- Author:
Shengxing WANG
1
;
Zhenyi JIN
1
;
Chunmin LI
1
;
Wangde ZHANG
1
;
Yang ZHANG
1
Author Information
1. 首都医科大学附属北京朝阳医院血管外科，北京 100020
- Publication Type:Journal Article
- Keywords:
Balloon;
Angioplasty;
Infrapopliteal artery;
Hemodialysis
- From:
Chinese Journal of General Surgery
2025;40(11):869-873
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of drug-coated balloons (DCB) in hemodialysis patients with peripheral artery disease (PAD) involving infrapopliteal lesions.Methods:A retrospective analysis was conducted on 53 hemodialysis patients (56 limbs, 66 lesions) with infrapopliteal PAD who underwent DCB treatment between Dec 2018 and Dec 2021. The primary outcome was improvement in Rutherford classification, while secondary outcomes included target lesion revascularization (TLR) and wound healing rate. Safety endpoints were all-cause mortality, amputation-free survival, and amputation rate.Results:The mean lesion length was (145.2±78.4) mm, and 87.5% of patients were of Rutherford grade ≥4. The median follow-up period was 14 months. Rutherford classification significantly improved at 3 and 12 months ( P< 0.001). At 12 months, TLR was 16.6%, wound healing rate was 68.6%, amputation-free survival was 73.2%, all-cause mortality was 19.8%, and amputation rate was 8.9%. Multivariate Cox regression indicated that high WIfI risk ( HR=3.936, 95% CI: 1.079-14.355, P=0.038) was an independent predictor of amputation-free survival. Conclusion:DCB is effective and safe for hemodialysis patients with infrapopliteal artery disease, while high WIfI risk predicts poor prognosis.
